



## **Dolutegravir as monotherapy in HIV-1-infected individuals with suppressed HIV viraemia**

C. Katlama, C. Soulié, F. Caby, A. Denis, C. Blanc, L. Schneider, M.-A. Valantin, R. Tubiana, M. Kirstetter, E. Valdenassi, et al.

### **► To cite this version:**

C. Katlama, C. Soulié, F. Caby, A. Denis, C. Blanc, et al.. Dolutegravir as monotherapy in HIV-1-infected individuals with suppressed HIV viraemia. *Journal of Antimicrobial Chemotherapy*, 2016, 71 (9), pp.2646-2650. 10.1093/jac/dkw186 . hal-01340219

**HAL Id: hal-01340219**

**<https://hal.sorbonne-universite.fr/hal-01340219>**

Submitted on 30 Jun 2016

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

version  
d'après)

**Dolutegravir as monotherapy in HIV-1 infected individuals  
with suppressed HIV viremia**

C Katlama<sup>1,2</sup>, C Soulié<sup>2,3</sup>, F Caby<sup>1,2</sup>, A Denis<sup>1</sup>, C Blanc<sup>1,2</sup>, L Schneider<sup>1,2</sup>, MA Valantin<sup>1,2</sup>,  
R Tubiana<sup>1,2</sup>, M Kirstetter<sup>1</sup>, E Valdenassi<sup>1</sup>, Thuy Nguyen<sup>2,3</sup>, G Peytavin<sup>4</sup>,  
V. Calvez<sup>2,3</sup>, AG Marcelin<sup>2,3</sup>.

<sup>1</sup>Hôpital Pitié-Salpêtrière, Infectious diseases Department, 75013, Paris, France.

<sup>2</sup>Sorbonne Universités, UPMC Univ Paris 06, INSERM, Institut Pierre Louis  
d'Epidémiologie et de Santé Publique (IPLESP UMRS 1136), 75013, Paris, France.

<sup>3</sup>Hôpital Pitié-Salpêtrière, Department of Virology, Paris, France

<sup>4</sup>Pharmaco-Toxicology Department, APHP, Bichat-Claude Bernard Hospital, Université Paris  
Diderot, Sorbonne Paris Cité, IAME, INSERM UMR 1137, Paris, France.

**Key words:** HIV, Antiretroviral therapy, Dolutegravir monotherapy

**Words count:** 1963 words

**Running title:** Dolutegravir monotherapy in HIV suppressed patients

**Corresponding author:**

Pr Christine Katlama, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service des Maladies  
Infectieuses et Tropicales, 75013, Paris, France.

E-mail: christine.katlama@aphp.fr

Phone: +33 (0) 1 42 16 01 42

Fax: +33 (0) 1 42 16 01 21

**Summary: 249 words (250)**

**Background:** Reducing drug burden is a key challenge for achieving long-life suppressive therapy. Dolutegravir with a high potency, long half-life and high genetic barrier offers potential for monotherapy.

**Methods:** This observational single center study enrolled all patients with HIV-RNA (VL) < 50 copies/ml for at least 12 months, CD4 > 350 cells/mm<sup>3</sup>, with no failure under integrase inhibitor who had switched suppressive antiretroviral therapy (ART) for dolutegravir monotherapy 50 mg/day. Primary outcome was proportion of patients with VL < 50 copies/mL at W24.

**Results:** Twenty eight patients treated for a median ART duration of 17 years (IQR:11-20), virally suppressed for 79 months (IQR:42-95) with a median 624 CD4 count (IQR:524-761) were enrolled. Baseline ART consisted in a 3-drug (n=10), a 2-drug (n=10) or single drug regimen (n=8) with integrase inhibitor exposure in 13 patients. The proportion of patients maintaining VL < 50 copies/mL was: 96% (95% CI: 79-100) at W4, 100% (85-100) at W8, 93% (76-99) at W12 and 92 % (75-99) at W24. Three patients (3.70%; 95% CI: 3.4-10.8) with prior integrase inhibitor experience had HIV-RNA rebound with presence of resistance mutations. Genotypic resistance in HIV-DNA using Sanger method or ultradeep sequencing showed no integrase inhibitor-RAM except for the mutation 74I in one on a suppressive elvitegravir-regimen. The median within- and between-subject variability of dolutegravir C24h was 25% and 34%, respectively. Nine patients with a year follow up remained virally suppressed.

**Conclusion:** Dolutegravir has the potency to be further investigated as single ART in randomized studies particularly in patients with no prior exposure to integrase inhibitor.

## 58 Introduction

59 The need for long-term ART in an aging HIV infected population is a challenging  
60 issue with a double objective: maintaining maximal viral suppression with a minimal  
61 treatment-associated toxicity. Because long-term virological success has become more and  
62 more frequent, and considering the high potency of the newest antiretroviral drugs, concepts  
63 in antiretroviral strategy are moving: towards the use of lighter antiretroviral strategies to  
64 maintain viral suppression, similarly to standard triple drug approach <sup>1-3</sup>.

65 Dolutegravir is the most recently licensed integrase inhibitor indicated in both naïve  
66 and pre-treated HIV infected patients <sup>4,5</sup>. As with first generation integrase inhibitor,  
67 dolutegravir has a high antiviral potency with an average 2 to 2.5 log<sub>10</sub> reduction in viral load  
68 leading to viral suppression within few weeks <sup>6-11</sup>. It exhibits a predictable pharmacokinetic  
69 profile, a well-defined exposure-response relationship and has shown a good safety profile  
70 with limited metabolic, renal or bone toxicity. In addition, dolutegravir has a minimal intra-  
71 and inter-pharmacokinetic variability and a low potential for drug-drug interactions by  
72 avoiding CYP 450 or UGT enzymes induction or inhibition <sup>12</sup>. In addition, unlike the other  
73 integrase inhibitor dolutegravir appears to have a more robust resistance profile. It remains  
74 efficient on HIV-1 strains harbouring raltegravir or elvitegravir resistance associated mutation  
75 and very few dolutegravir resistance associated mutation has been selected in patients failing  
76 a dolutegravir-based regimen <sup>7-10</sup>.

77 Here, we wanted to report our experience of dolutegravir as monotherapy in heavily  
78 pre-treated HIV-1 infected individuals.

79  
80  
81  
82

## Patients and Methods

This observational study evaluated all patients followed at the HIV clinical unit of Infectious Diseases department at Pitie-Salpetriere hospital (Paris, France) who were switched from any ART to dolutegravir 50 mg once daily from May 2014 to January 2015, with a plasma (p) HIV-1 RNA below 50 copies/mL for at least 12 months on ART, without history of virological failure on integrase inhibitor, and nor hepatitis B or C co-infection, nor pregnancy.

This observational study used the clinical and biological data of all patients who gave their consent to have their clinical and biological data recorded in an electronic medical record (NADIS). As part of routine clinical work under the responsibility of an HIV specialist, all patients were informed and consented to ART modification.

The primary outcome was the proportion of individuals with pHIV-1 RNA < 50 copies/mL at week 24. Secondary outcomes included resistance profile in case of viral rebound, dolutegravir plasma concentrations. Virological failure was defined as 2 consecutive values of pHIV-1 RNA  $\geq$  50 copies/mL two weeks apart or one value > 200 copies/mL. As part of routine procedure in any antiretroviral regimen modification, pHIV-1 RNA and CD4 cells count are routinely assessed at day 0, week 4-8, week 12, week 24 and every six months thereafter. Plasma HIV-1 RNA was quantified using the Cobas AmpliPrep/CobasTaqMan HIV-1 assay version 2.0 (Roche Diagnostics; lower detection limit of 20 copies/mL). Below this cut-off, the assay indicates the qualitative detection of pHIV-1 RNA in the range of 1 to 20 copies/mL. Quantification of whole blood HIV DNA level and resistance testing were performed retrospectively on frozen samples at day 0 and week 24 using a real-time PCR method as previously described<sup>13</sup>. Genotypic resistance testing was performed in HIV DNA and in HIV RNA in case of virological rebound using Sanger methods and was interpreted using ANRS genotypic algorithm (<http://www.hivfrenchresistance.org>).

To search for resistant minority variants, Ultradeep sequencing was performed retrospectively on HIV integrase gene using Illumina technology. Briefly, a 573 bp fragment was PCR-amplified<sup>14</sup> and the Nextera XT DNA Library Preparation Kit (Illumina®, San Diego, USA) allowed the preparation of sequencing-ready libraries rapidly sequenced with MiSeq Illumina system. Presence of minority resistant variants (>5%) were analyzed with Smartgene®.

Dolutegravir plasma concentrations were determined on frozen sample (C24h) at week 4-8, week 12 and week 24 using liquid chromatography-tandem mass spectrometry (Waters Acquity UPLC-TQD; lower limits of quantification 5 ng/mL). Any value above 1,000 ng/mL was considered as adequate as it has been reported associated with a 80% probability of reaching HIV-RNA < 50 copies/mL at week 48<sup>15</sup>.

Continuous variables were expressed as median and interquartile range. Nominal variables were expressed as percentages. Statistics analyses were performed using SAS 9.3 (SAS Institute, Cary, NC, USA).

## **Results**

### *Study population*

Twenty-eight individuals were evaluated. All were followed up to week 24 and all except one remained on dolutegravir monotherapy during this period. Baseline characteristics are shown in table 1. They were middle-aged patients with a long ART history of 17 years [11-20], virologically suppressed for a median of 6.6 years [3.5 -7.9]. Two thirds of patients (n=19) had a pHIV-1 RNA < 1 copy/mL. Baseline antiretroviral therapy consisted in triple drug strategy (36%), dual therapy (32%) and monotherapy (32%). Thirteen had been previously exposed to integrase inhibitor (raltegravir n=12, elvitegravir n=1) and six of them were on an integrase inhibitor containing regimen before switching to dolutegravir monotherapy.

## 132 *Efficacy*

133       At week 24, the proportion of patients with a pHIV-1 RNA < 50 copies/mL was 89%  
134 (25/28; 95% CI 72-98). It was 100% (85-100) at week 4 (23/23), 100% (85-100) at week 8  
135 (22/22) and 96% (82-99) at week 12 (27/28). All the 19 patients with a baseline pHIV-1 RNA  
136 < 1 copy/mL remained so over the study period. Three patients had virological failure (Figure  
137 1).

138       - Patient 1 is a 35 year-old female with a CD4 nadir of 262 cells/mm<sup>3</sup>, on ART for 7  
139 years, with a plasma HIV-1 viremia suppressed for 6.7 years, a baseline CD4 count of 525  
140 cells/mm<sup>3</sup> and HIV DNA of 310 copies/10<sup>6</sup> cells. She had been suppressed on raltegravir and  
141 etravirine during seven months then switched to tenofovir/ emtricitabine/ ritonavir-boosted  
142 darunavir because of pregnancy. After delivery, she was switched to dolutegravir  
143 monotherapy. Dynamics of viral load is shown on Figure 1. Virological failure occurred at  
144 week 24 (2220 copies/mL) with emergence of resistance mutations to all integrase inhibitors  
145 (Figure 1). No mutation was detected in the HIV-1 DNA at baseline nor at week 13.  
146 Dolutegravir plasma concentrations were above adequate values at week 4, 12 and 24.

147       - Patient 2 is a 56 year-old man, with a CD4 nadir of 60 cells/mm<sup>3</sup>, on ART for 18  
148 years with a pHIV-1 viremia suppressed for 17 months, a baseline CD4 count of 1108  
149 cells/mm<sup>3</sup> and a total HIV-1 DNA of 1459 /10<sup>6</sup> cells. Prior to dolutegravir monotherapy, he  
150 received tenofovir/ emtricitabine/ cobicistat-boosted elvitegravir for seven months with three  
151 assessments of pHIV-1 RNA < 20 copies/mL. At week 12, virological failure was detected  
152 (pHIV-1 RNA=138 then 469 copies/mL) with presence of the E92Q mutation on the integrase  
153 gene that confers resistance to raltegravir and elvitegravir (Figure 1) and L74I. Baseline  
154 genotyping resistance test on HIV-1 DNA revealed retrospectively the presence of the L74I  
155 mutation.

- Patient 3 is a 57 year-old man, with a CD4 nadir of 233 cells/mm<sup>3</sup>, on ART for 6 years with a pHIV viremia suppressed for 5.8 years, a baseline CD4 count of 940 cells/mm<sup>3</sup> and a total HIV-1 DNA of 174 copies/10<sup>6</sup> cells. He received tenofovir/emtricitabine/ raltegravir for 72 months with a pHIV-1 RNA < 20 copies on 23 measurements except for one value of 37 copies. Virological failure occurred at week 24, (pHIV-1 RNA=291 copies/mL) associated with emergence of the N155H mutation, conferring resistance to raltegravir, elvitegravir and dolutegravir 50 mg (Figure 1).

#### *Ultra-deep sequencing*

Twenty-five patients were evaluated at baseline for presence of integrase inhibitor minority resistant variants (MRV) in HIV DNA. None of the three patients with virological rebound had MRV in integrase gene. Two patients had MRV in integrase gene: E138K (6.6%); G140S (5.4%); N155H (8.1%) leading to resistant for all integrase inhibitor in one patient and S147G (8.2%) leading to elvitegravir resistance in the second patient. Both had been exposed to integrase inhibitor in the past with no virological failure. Importantly none of them experienced virological failure on dolutegravir monotherapy had MRV with a follow up of 15 months.

#### *Plasma drug concentrations*

Median (IQR25-75%) values for dolutegravir plasma C24h were 1,411 ng/mL (1,014-1,745), 1,699 ng/mL (1,441-1,912) and 1,571 ng/mL (1,252-1,913) in the 28 patients, at Week 4-8, Week 12 and Week 24, respectively. All C24h were above the *in vitro*, protein-adjusted 90 % inhibitory concentration (IC<sub>90</sub>) of dolutegravir for wild-type virus (64 ng/mL). Five patients had 6 measurements below threshold (1,000 ng/mL). The median within- and between-subject variability of dolutegravir C24h determined in the 28 patients with approximately 3 values per patient over the follow up were 25% and 34%, respectively.



## Discussion

This study reports our experience of using dolutegravir as monotherapy in highly treatment-experienced HIV infected patients with long-term suppressed viremia. Indeed, there is currently a need, in real life, for lighter antiretroviral regimen leading to less cumulative drug exposure. There are two main findings in our study: first, a potential for using dolutegravir as a monotherapy with a large proportion of patients maintaining viral suppression with a suppression rate of 89% at week 24. Secondly, as resistance mutations were evidenced in three patients, the suggestion that the genetic barrier to resistance for dolutegravir, high in naïve patients<sup>7</sup>, can be challenged when used as a single agent in this population of patients with an ART history of over 15 years and integrase inhibitor experience for nearly half of them.

None of the three patients with virological rebound, had compliance issues. There was no co-medication that could induce drug-drug interactions as attested by dolutegravir plasma concentrations. Finally no mutation conferring resistance to dolutegravir was found in HIV DNA neither by standard Sanger assay nor by Ultradeep sequencing assay. However, the mutation L74I, evidenced in one patient prior to switch, associated to a possible low resistance level according to Stanford interpretation (<http://hivdb.stanford.edu/>) contrarily to the ANRS one, may have favored virological rebound. One possible explanation for virologic rebound could be the acquisition at low level of integrase resistance mutations during the previous raltegravir or elvitegravir containing regimen. However, our results using ultradeep sequencing for those patients do not favor this hypothesis. Indeed, we know that raltegravir can select resistance mutations even at low level of replication<sup>16,17</sup> and dolutegravir can also select integrase resistance mutations, such as N155H and R263K, in experienced patients, but integrase inhibitors naïve<sup>18</sup>. In this study, the R263K mutation was not evidenced at failure as previously described<sup>18,19</sup>. The patients reported in the SAILING study<sup>18</sup> were integrase inhibitor-naïve and on a triple dolutegravir-containing regimen once daily while the three patients here were integrase inhibitor-experienced (raltegravir or elvitegravir-experienced but dolutegravir-naïve), which could explain the difference in integrase resistance mutation selection.

With regards to dolutegravir pharmacologic monitoring, we confirm here the pharmacologic robustness of dolutegravir with a low coefficient of variation of 25% compared to raltegravir and elvitegravir with values of 212 % and 33–72 % respectively<sup>20,21</sup>.

This study has several limitations. It is an observational, single center study, on a limited number of patients with a short follow-up. However, our routine management of patients with blood storage and standardized monitoring is close to clinical trials assessments allowing assessments of dolutegravir concentrations and genotypic testing in HIV DNA both using Sanger method and Ultradeep sequencing.

Gubavu et al <sup>22</sup> reported the successful switch to dolutegravir monotherapy over a median follow-up of 32 weeks in 21 patients very similar to our study population except for much less frequent exposure to integrase inhibitor. Similarly, Rojas et al reported <sup>23</sup> their experience of 31 patients, heavily pretreated mostly under a protease inhibitor-containing regimen of successful switch to dolutegravir 50 mg once daily monotherapy.

In summary, these pilot experiences from real life suggesting potential for using dolutegravir monotherapy have to be evaluated in randomized clinical trials. According to our results, pre-exposure to integrase inhibitors should be viewed with great caution in this context as episodes of viral replication could have enhanced the emergence of integrase resistance mutations.

**Acknowledgements**

This work was presented in part at the Fifteenth European AIDS Conference EACS, Barcelona Spain 2015 (oral presentation PS 4/4)

**Funding**

This study was carried out as part of our routine work with internal fund for ultradeep sequencing analysis.

**Transparency declarations**

CK had served on advisory board for Merck-Sharpe-Dohme MSD, Janssen and clinical investigator for MSD, Janssen, ViiV Health Care.

All other authors: none to declare.

**Author contributions**

CK, CS, FC, AD, AGM, VC participated in the conception and design of the study.

CK, FC, LS, MAV, RT, MK included the patients in the study.

CB, LS collected the clinical data. C.K C.S, AG.M analysed and interpreted the data.

CS, AG. M, VC performed the virology analysis.

GP performed the pharmacology analysis.

CK, CS, FC, AG. M wrote the manuscript.

All the authors reviewed, revised for content and approved the final version of this paper.

All the authors reviewed, revised for content and approved the final version of this paper.

## References

1. ENCORE1 Study Group. Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. *Lancet Infect Dis* 2015; **15**: 793–802.
2. Cahn P, Andrade-Villanueva J, Arribas JR, *et al*. Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naïve adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial. *Lancet Infect Dis* 2014; **14**: 572–80.
3. Raffi F, Babiker AG, Richert L, *et al*. Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naïve adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial. *Lancet* 2014; **384**: 1942–51.
4. European AIDS Clinical Society, Guidelines, Version 8.0 October 2015.pdf. <http://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html>
5. Adult and Adolescent ARV Guidelines | AIDSinfo. <https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-treatment-guidelines/0>.
6. Min S, Sloan L, DeJesus E, *et al*. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults. *AIDS* 2011; **25**: 1737–45.
7. Stellbrink H-J, Reynes J, Lazzarin A, *et al*. Dolutegravir in antiretroviral-naïve adults with HIV-1: 96-week results from a randomized dose-ranging study. *AIDS* 2013; **27**: 1771–8.
8. Walmsley SL, Antela A, Clumeck N, *et al*. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. *N Engl J Med* 2013; **369**: 1807–18.
9. Raffi F, Jaeger H, Quiros-Roldan E, *et al*. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naïve adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. *Lancet Infect Dis* 2013; **13**: 927–35.
10. Clotet B, Feinberg J, van Lunzen J, *et al*. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naïve adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. *Lancet* 2014; **383**: 2222–31.
11. Cahn P, Pozniak AL, Mingrone H, *et al*. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naïve adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. *Lancet* 2013; **382**: 700–8.
12. Cottrell ML, Hadzic T, Kashuba ADM. Clinical pharmacokinetic, pharmacodynamic

and drug-interaction profile of the integrase inhibitor dolutegravir. *Clin Pharmacokinet* 2013; **52**: 981–94.

13. Avettand-Fènoël V, Chaix M-L, Blanche S, *et al*. LTR real-time PCR for HIV-1 DNA quantitation in blood cells for early diagnosis in infants born to seropositive mothers treated in HAART area (ANRS CO 01). *J Med Virol* 2009; **81**: 217–23.

14. Malet I, Delelis O, Soulie C, *et al*. Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients. *J Antimicrob Chemother* 2009; **63**: 795–804.

15. Jung BH, Rezk NL, Bridges AS, *et al*. Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry. *Biomed Chromatogr BMC* 2007; **21**: 1095–104.

16. Malet I, Fourati S, Morand-Joubert L, *et al*. Risk factors for raltegravir resistance development in clinical practice. *J Antimicrob Chemother* 2012; **67**: 2494–500.

17. Lambert-Niclot S, George EC, Pozniak A, *et al*. Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART. *J Antimicrob Chemother* 2016; **71**: 1056–62.

18. Underwood M, DeAnda F, Dorey D, *et al*. Resistance Post Week 48 in ART-Experienced, Integrase Inhibitor-Naive Subjects With Dolutegravir (DTG) vs. Raltegravir (RAL) in SAILING (ING111762). 13<sup>th</sup> EU Meeting on HIV and Hepatitis; 2015, Barcelona, Spain. *Abstract 6*.

19. Quashie PK, Mesplède T, Han Y-S, *et al*. Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir. *J Virol* 2012; **86**: 2696–705.

20. Adams JL, Greener BN, Kashuba AD. Pharmacology of HIV Integrase Inhibitors. *Curr Opin HIV AIDS* 2012; **7**: 390–400.

21. DeJesus E, Berger D, Markowitz M, *et al*. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naïve and treatment-experienced patients. *J Acquir Immune Defic Syndr* 2006; **43**: 1–5.

22. Gubavu C, Prazuck T, Niang M, *et al*. Dolutegravir-based monotherapy or dual therapy maintains a high proportion of viral suppression even in highly experienced HIV-1-infected patients. *J Antimicrob Chemother* 2016; **71**: 1046–50.

23. Rojas J, Blanco J.L, Lonca M, *et al*. Dolutegravir monotherapy in HIV-infected patients with sustained viral suppression : a 24-week pilot study. 15<sup>th</sup> European AIDS Conference; 2015; Barcelona, Spain. *Abstract LBPS 4/2*.